The Invisible Graveyard: Quantifying the Mortality Cost of FDA Efficacy Lag

Abstract: This study quantifies the cumulative mortality and morbidity costs associated with the Unitary Pre-Market Approval (UPMA) model mandated by the 1962 Kefauver-Harris Amendments. By enforcing efficacy testing prior to market entry, the current regulatory framework imposes an average "Efficacy Lag" of 8.2 years (95% CI: 4.85 years-11.5 years) post-safety verification. Using data from the Tufts Center for the Study of Drug Development (CSDD) and the WHO Global Burden of Disease (GBD) database, we estimate two distinct mortality costs: (1) Historical mortality (1962-2024): approximately 102M deaths (95% CI: 36.9M deaths-214M deaths) died waiting for approved drugs during their approval delays, representing a lower bound excluding drugs never developed due to cost barriers; (2) Future timeline shift: an additional 416M deaths (95% CI: 225M deaths-630M deaths) will eventually die because the disease eradication timeline has been pushed back by 8.2 years (95% CI: 4.85 years-11.5 years). Combined, these represent 7.94B DALYs (95% CI: 4.43B DALYs-12.1B DALYs) Disability-Adjusted Life Years when adjusted for morbidity, with a cumulative economic deadweight loss of approximately \$1.19 quadrillion (95% CI: \$443T-\$2.41 quadrillion) (2024 USD). The societal cost of Type II Regulatory Errors (delayed access to effective therapies) exceeds the averted cost of Type I Regulatory Errors (market access for ineffective therapies) by a factor of 3.07k:1 (95% CI: 2.88k:1-3.12k:1). Summary: After proving a drug is safe, the FDA requires 8.2 years to prove it works before patients can access it. We estimate this delay cost 102M deaths among people waiting for approved drugs (1962-2024). The cost of blocking good drugs is 3.07k:1 higher than the cost of approving bad ones.